Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert⁺/⁻) mice.

Kyzar EJ, Stewart AM, Kalueff AV.

Behav Brain Res. 2016 Jan 1;296:47-52. doi: 10.1016/j.bbr.2015.08.018. Epub 2015 Sep 1.

PMID:
26340513
2.

Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.

Toftdahl NG, Nordentoft M, Hjorthøj C.

Soc Psychiatry Psychiatr Epidemiol. 2016 Jan;51(1):129-40. doi: 10.1007/s00127-015-1104-4. Epub 2015 Aug 11.

PMID:
26260950
3.

Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

Majić T, Schmidt TT, Gallinat J.

J Psychopharmacol. 2015 Mar;29(3):241-53. doi: 10.1177/0269881114568040. Epub 2015 Feb 9. Review.

PMID:
25670401
4.

Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review.

Rothbart R, Stein DJ.

Expert Opin Pharmacother. 2014 Dec;15(18):2709-19. doi: 10.1517/14656566.2014.972936. Review.

PMID:
25399534
5.

Psilocybin and Obsessive Compulsive Disorder.

Wilcox JA.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):393-5. doi: 10.1080/02791072.2014.963754.

PMID:
25364991
6.

The Heffter Research Institute: past and hopeful future.

Nichols DE.

J Psychoactive Drugs. 2014 Jan-Mar;46(1):20-6.

PMID:
24830182
7.

A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains.

Proietti Onori M, Ceci C, Laviola G, Macrì S.

Behav Brain Res. 2014 Jul 1;267:95-105. doi: 10.1016/j.bbr.2014.03.023. Epub 2014 Mar 24.

PMID:
24675156
8.

Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice.

Egashira N, Okuno R, Shirakawa A, Nagao M, Mishima K, Iwasaki K, Oishi R, Fujiwara M.

Biol Pharm Bull. 2012;35(3):376-9.

9.

Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.

Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH.

Pharmacol Biochem Behav. 2011 Mar;98(1):21-7. doi: 10.1016/j.pbb.2010.12.002. Epub 2010 Dec 8.

10.

Cannabinoids for Tourette's Syndrome.

Curtis A, Clarke CE, Rickards HE.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006565. doi: 10.1002/14651858.CD006565.pub2. Review.

PMID:
19821373
11.

Effects of Psilocybe argentipes on marble-burying behavior in mice.

Matsushima Y, Shirota O, Kikura-Hanajiri R, Goda Y, Eguchi F.

Biosci Biotechnol Biochem. 2009 Aug;73(8):1866-8. Epub 2009 Aug 7.

12.

Improvement in refractory obsessive compulsive disorder with dronabinol.

Schindler F, Anghelescu I, Regen F, Jockers-Scherubl M.

Am J Psychiatry. 2008 Apr;165(4):536-7. doi: 10.1176/appi.ajp.2007.07061016. No abstract available.

PMID:
18381920
13.

The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder.

Flaisher-Grinberg S, Klavir O, Joel D.

Int J Neuropsychopharmacol. 2008 Sep;11(6):811-25. doi: 10.1017/S146114570800847X. Epub 2008 Mar 14.

PMID:
18339223
14.

Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.

Marchesi C, Tonna M, Maggini C.

World J Biol Psychiatry. 2009;10(4 Pt 2):599-602.

PMID:
17853269
15.

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL.

J Clin Psychiatry. 2006 Nov;67(11):1735-40.

PMID:
17196053
16.

Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.

Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH.

Neuropsychopharmacology. 2007 May;32(5):1032-41. Epub 2006 Oct 18.

17.

Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder.

El Mansari M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):362-73. Epub 2006 Jan 20. Review.

PMID:
16427729
18.

SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.

Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, Shuster L.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.

PMID:
16061378
19.

Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder.

Delorme R, Betancur C, Callebert J, Chabane N, Laplanche JL, Mouren-Simeoni MC, Launay JM, Leboyer M.

Neuropsychopharmacology. 2005 Aug;30(8):1539-47.

20.

Mood in relation to subclinical obsessive-compulsive symptoms.

Spinella M.

Int J Neurosci. 2005 Apr;115(4):433-43.

PMID:
15809213
Items per page

Supplemental Content

Loading ...
Write to the Help Desk